What You Should Know:
– Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a new biotechnology company specializing in polymerase chain reaction (PCR)-based infectious disease detection.
– The merger creates one of the world’s first fully vertically-integrated molecular testing platforms.
Addressing Cost and Complexity in PCR Testing
OSPRI will develop and deliver advanced tools to improve access to high-quality care across various healthcare segments, including women’s health, primary care, urgent care, hospitals, and clinical reference laboratories. The company’s end-to-end solution covers assay development, manufacturing, lab buildout, revenue cycle management, and regulatory support. This empowers providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.
Merger Impact
The merger is financed by up to $30M in strategic funding from Catalio Capital Management, a healthcare investment firm. This partnership will support OSPRI’s continued growth, platform development, and national expansion.
OSPRI was built on the complementary strengths of its founding entities. Community Direct DX has launched over 60 labs nationwide. Scienetix brings expertise in molecular bioengineering, while Advanta R&D has contributed to advancements in high-resolution genomics and national public health initiatives. With its headquarters in McKinney, Texas, OSPRI currently serves clients in 20 states. The company plans to expand its R&D team by 40% and grow its commercial operations by 25% over the next 12-24 months to meet increasing demand.
“PCR testing is foundational for infectious disease detection, but cost and complexity have kept it out of reach for many,” said Steve M. Sorey, Partner at OSPRI. “To unlock widespread adoption, we must reduce both. At OSPRI, we’re obsessed with doing more with less—making PCR faster, cheaper, and better for everyone involved.”
